Match Document Document Title
US20160158150 Manufacture of Pharmaceutical Compositions  
The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically...
US20160031893 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME  
The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and reducing the risk...
US20150224130 Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical Compositions  
The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one...
US20150210681 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS  
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with...
US20140193347 LIPID DEPOT FORMULATIONS  
The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least...
US20140072623 GASTRIC RETAINED GABAPENTIN DOSAGE FORM  
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
US20130023525 GYRASE INHIBITORS AND USES THEREOF  
The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions...
US20120138056 DRY POWDER COMPOSITION COMPRISING CO-JET MILLED PARTICLES FOR PULMONARY INHALATION  
The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically...
US20090297619 NANOPARTICULATE ANTICONVULSANT AND IMMUNOSUPPRESSIVE COMPOSITIONS  
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the...
US20090169620 ORALLY DISINTEGRATING TABLET COMPOSITIONS OF TEMAZEPAM  
The compositions of the present invention are orally disintegrating tablet compositions comprising a therapeutically effective amount of at least one drug such as temazepam, 0.5-3% of an ODT...
US20090162441 PULMONARY DELIVERY IN TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM  
A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the...
US20080248123 Nanoparticulate anticonvulsant and immunosuppressive compositions  
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the...
US20080069878 Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs  
The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical...
US20070036854 Therapeutic applications of pro-apoptotic benzodiazepines  
Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of...
US20060198896 Aerosol and injectable formulations of nanoparticulate benzodiazepine  
Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of...
US20050288278 HIV replication inhibiting pyrimidines  
This invention concerns the use of compounds of formula the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein...
US20050158249 Aerodynamically light particles for pulmonary drug delivery  
Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically...
US20170151259 METHOD FOR THE TREATMENT OF DRAVET SYNDROME  
A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its...
US20170151257 METHOD FOR THE TREATMENT OF DRAVET SYNDROME  
A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its...
US20170056344 METHODS OF TREATING LENNOX-GASTAUT SYNDROME USING FENFLURAMINE  
A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by...
US20160184311 Combination Therapy for the Treatment of Cancer  
The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is...
US20150118301 Immediate Release Abuse-Deterrent Granulated Dosage Forms  
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including...
US20150118300 Immediate Release Abuse-Deterrent Granulated Dosage Forms  
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including...
US20140038935 DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES  
The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of...
US20120087952 Pulmonary Delivery in Treating Disorders of the Central Nervous System  
A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the...
US20120003330 BENZOQUINOLONE INHIBITORS OF VMAT2  
The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.
US20090304801 AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE  
Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of...
US20090258865 ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS  
The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
US20090111792 Injectable capsaicin with tricyclic antidepressant adjunctive agent  
Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and...
US20090012065 Therapeutic applications of pro-apoptotic benzodiazepines  
Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of...
US20070129353 Alpha-helix mimetics and method relating to the treatment of cancer stem cells  
The invention provides α-mimetic structures and a chemical library relating thereto. Additionally, the invention provides methods wherein a-mimetic compounds are used to treat cancer stem cells.
US20070071687 INTRANASAL BENZODIAZEPINE COMPOSITIONS  
A pharmaceutical composition for intranasal administration to a mammal. The pharmaceutical composition comprises an effective amount of a benzodiazepine or pharmaceutically acceptable salt...
US20160158220 BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2  
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.
US20140242063 PHARMACEUTICAL COMPOSITIONS  
The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g.,...
US20140170220 MULTIMODAL PARTICULATE FORMULATIONS  
Multimodal particulate formulations of medicaments and methods for their use, e.g. by nasal or pulmonary administration for the treatment of various medical conditions, are provided.
US20140128378 METHODS OF TREATING EPILEPTOGENESIS  
The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus.
US20140093559 ABUSE-PROOFED DOSAGE FORM  
A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse...
US20130195935 ABUSE-PROOFED DOSAGE FORM  
A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse...
US20120308654 ABUSE-PROOFED DOSAGE FORM  
A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse...
US20120165301 BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS  
The present invention provides, for example, pharmaceutical compositions comprising a benzodiazepine compound and an agent selected from the group consisting of a topical steroid, a keratolytic...
US20120135071 Abuse-proofed dosage form  
A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse...
US20100055133 PHARMACEUTICAL COMPOSITIONS  
The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g.,...
US20090041800 Methods for Treating Dependence  
Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided...
US20060009447 Pharmaceutical compositions comprising midazolam in a high concentration  
Compositions of midazolam, a benzodiazapine, in concentrations of 35-100 mg/ml are disclosed for the treatment of anxiety, epilepsy and epileptic seizures, invasive surgical procedures and...
US20050025717 Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders  
Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in...
US20170000728 Controlled-Release CNS Modulating Compositions and Methods for the Treatment of Otic Disorders  
Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an...
US20150313868 USE OF CANNABINOIDS AND TERPENES FOR TREATMENT OF ORGANOPHOSPHATE AND CARBAMATE TOXICITY  
Pharmaceutical compositions in which isolated cannabinoid receptor modulators are optionally combined with terpene blends in a pharmaceutically acceptable carrier. Methods for treating or...
US20150174116 TRANSMUCOSAL DRUG DELIVERY SYSTEM  
Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic...
US20150157558 METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE FORM  
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
US20150118295 Immediate Release Abuse-Deterrent Granulated Dosage Forms  
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including...